for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Inovio Pharmaceuticals Inc

INO.O

Latest Trade

14.34USD

Change

-0.52(-3.50%)

Volume

15,648,501

Today's Range

13.75

 - 

14.55

52 Week Range

1.92

 - 

19.36

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
14.86
Open
14.52
Volume
15,648,501
3M AVG Volume
912.35
Today's High
14.55
Today's Low
13.75
52 Week High
19.36
52 Week Low
1.92
Shares Out (MIL)
158.10
Market Cap (MIL)
2,349.31
Forward P/E
-21.58
Dividend (Yield %)
--

Next Event

Inovio Pharmaceuticals Inc Annual Shareholders Meeting

Latest Developments

More

Inovio Pharmaceuticals Says It Files Prospectus Supplement Related To $100 Million Common Stock Offering

Richter-Helm Biologics expands deal to support COVID-19 DNA vaccine trials

Inovio And Geneone Life Science Report Positive Phase 1/2A Clinical Data With Dna Vaccine Ino-4700 For Mers Coronavirus

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals, Inc. (Inovio) is a late-stage biotechnology company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company's DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases. It has completed, current or planned clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus (HIV), Ebola, Middle East Respiratory Syndrome (MERS) and Zika virus. With its immunotherapy platform, as well as with its CELLECTRA electroporation delivery technology, it has a pipeline of pre-clinical and clinical stage products that have generated in vivo immune responses.

Industry

Biotechnology & Drugs

Contact Info

6769 Mesa Ridge Rd

SAN DIEGO, CA

92121-2995

United States

+1.858.4103134

http://www.inovio.com/

Executive Leadership

Simon X. Benito

Independent Chairman of the Board

Jong Joseph Kim

President, Chief Executive Officer, Director

Peter D. Kies

Chief Financial Officer

Jacqueline Elizabeth Elizabeth Shea

Chief Operating Officer

Laurent M Humeau

Chief Scientific Officer

Key Stats

2.25 mean rating - 8 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019

0.0K

2020(E)

0.0K
EPS (USD)

2017

-1.080

2018

-1.050

2019

-1.210

2020(E)

-0.689
Price To Earnings (TTM)
--
Price To Sales (TTM)
900.36
Price To Book (MRQ)
11.76
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
41.53
LT Debt To Equity (MRQ)
41.53
Return on Investment (TTM)
-53.64
Return on Equity (TTM)
-46.94

Latest News

Latest News

Inovio says COVID-19 vaccine produces antibodies in mice, guinea pigs

U.S. immunotherapy company Inovio Pharmaceuticals Inc <INO.O> said on Wednesday its experimental vaccine to prevent coronavirus infection produced protective antibodies and immune system responses in mice and guinea pigs.

Inovio says COVID-19 vaccine produces antibodies in mice, guinea pigs

U.S. immunotherapy company Inovio Pharmaceuticals Inc on Wednesday said its experimental vaccine to prevent coronavirus infection was shown to produce protective antibodies and immune system responses in mice and guinea pigs.

BRIEF-Inovio Says 85% Of Glioblastoma Patients Treated With INO-5401 Combined with Libtayo Alive for at least 12 Months

* INOVIO'S INO-5401 IN COMBINATION WITH PD-1 INHIBITOR LIBTAYO® (CEMIPLIMAB) DEMONSTRATES 85% OF NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS ARE ALIVE 12 MONTHS FOLLOWING TREATMENT Source text for Eikon: Further company coverage:

BRIEF-Inovio Pharmaceuticals Says It Files Prospectus Supplement Related To $100 Million Common Stock Offering

* INOVIO PHARMACEUTICALS SAYS IT FILES PROSPECTUS SUPPLEMENT RELATED TO $100 MILLION COMMON STOCK OFFERING - SEC FILING Source text: (https://bit.ly/2WP0BrL) Further company coverage:

BRIEF-Richter-Helm Biologics expands deal to support COVID-19 DNA vaccine trials

* RICHTER-HELM BIOLOGICS AND INOVIO TO EXPAND EXISTING DNA MANUFACTURING AGREEMENT TO SUPPORT LARGE-SCALE MANUFACTURING OF INOVIO'S INVESTIGATIONAL DNA VACCINE FOR COVID-19

BRIEF-Inovio And Geneone Life Science Report Positive Phase 1/2A Clinical Data With Dna Vaccine Ino-4700 For Mers Coronavirus

* INOVIO AND GENEONE LIFE SCIENCE REPORT POSITIVE PHASE 1/2A CLINICAL DATA WITH DNA VACCINE INO-4700 FOR MERS CORONAVIRUS AT THE AMERICAN SOCIETY OF GENE & CELL THERAPY (ASGCT) CONFERENCE

BRIEF-Inovio Completes Enrollment In The Phase 1 U.S. Trial Of Ino-4800 For Covid-19 Dna Vaccine Interim Results Expected In June

* INOVIO COMPLETES ENROLLMENT IN THE PHASE 1 U.S. TRIAL OF INO-4800 FOR COVID-19 DNA VACCINE; INTERIM RESULTS EXPECTED IN JUNE

BRIEF-Ivi, Inovio, And Knih To Partner With Cepi In Phase 1/2 Clinical Trial Of Inovio's Covid-19 Dna Vaccine In South Korea

* IVI, INOVIO, AND KNIH TO PARTNER WITH CEPI IN PHASE 1/2 CLINICAL TRIAL OF INOVIO'S COVID-19 DNA VACCINE IN SOUTH KOREA

BRIEF-Inovio Initiates Phase 1 Clinical Trial Of Its Covid-19 Vaccine

* INOVIO INITIATES PHASE 1 CLINICAL TRIAL OF ITS COVID-19 VACCINE AND PLANS FIRST DOSE TODAY

BRIEF-Inovio Pharmaceuticals Filed Prospectus Supplement Pursuant To Sales Agreement For Offering Of Up To $150 Million

* INOVIO PHARMACEUTICALS- FILED PROSPECTUS SUPPLEMENT PURSUANT TO SALES AGREEMENT FOR OFFERING OF UP TO $150 MILLION

BRIEF-Inovio Pharmaceuticals Says Entered Into An At-The-Market Equity Offering Sales Agreement With Stifel, Nicolaus & Co

* INOVIO PHARMACEUTICALS INC - ENTERED INTO AN AT-THE-MARKET EQUITY OFFERING SALES AGREEMENT WITH STIFEL, NICOLAUS & CO

BRIEF-Inovio Interim Results Of An Open-Label Phase 2 Trial Of Vgx-3100 Show Efficacy Against Hpv-Associated Vulvar Dysplasia

* INOVIO INTERIM RESULTS OF AN OPEN-LABEL PHASE 2 TRIAL OF VGX-3100 SHOW EFFICACY AGAINST HPV-ASSOCIATED VULVAR DYSPLASIA

BRIEF-Inovio Reports Positive Interim Phase 2 VGX-3100 Results In Patients With HPV-Associated Anal Dysplasia

* INOVIO REPORTS POSITIVE INTERIM PHASE 2 VGX-3100 RESULTS IN PATIENTS WITH HPV-ASSOCIATED ANAL DYSPLASIA

BRIEF-Ology Bioservices, Inovio Partner To Manufacture COVID-19 DNA Vaccine With $11.9 Mlon Department Of Defense Grant

* OLOGY BIOSERVICES, INOVIO PARTNER TO MANUFACTURE COVID-19 DNA VACCINE WITH $11.9 MILLION DEPARTMENT OF DEFENSE GRANT

BRIEF-Inovio Pharmaceuticals Files For Mixed Shelf Of Up To $400 Million

* INOVIO PHARMACEUTICALS INC FILES FOR MIXED SHELF OF UP TO $400 MILLION - SEC FILING Source: (http://bit.ly/2WdfzJE) Further company coverage:

BRIEF-Inovio Pharmaceuticals Reports Q4 Revenue Of $279,000

* INOVIO PHARMACEUTICALS REPORTS 2019 FOURTH QUARTER AND YEAR-END FINANCIAL RESULTS

BRIEF-Inovio Pharmaceuticals Says "We Are Confident That We Have A Viable Approach To Address The Covid-19 Outbreak"

* INOVIO PHARMACEUTICALS SAYS "WE ARE CONFIDENT THAT WE HAVE A VIABLE APPROACH TO ADDRESS THE COVID-19 OUTBREAK"

BRIEF-Inovio Pharma Says Entered Into Amendment No. 2 To At-Market Equity Offering Sales Agreement

* INOVIO PHARMACEUTICALS SAYS ON MARCH 9, ENTERED INTO AMENDMENT NO. 2 TO AT--MARKET EQUITY OFFERING SALES AGREEMENT DATED MAY 25, 2018 - SEC FILING

BRIEF-Inovio Accelerates Timeline For COVID-19 DNA Vaccine INO-4800

* INOVIO ACCELERATES TIMELINE FOR COVID-19 DNA VACCINE INO-4800

BRIEF-Inovio Pharmaceuticals Inc Says On Feb 7, Co Entered Into An Amendment To At-The-Market Equity Offering Sales Agreement Dated May 25, 2018

* INOVIO PHARMACEUTICALS INC - ON FEB 7, CO ENTERED INTO AN AMENDMENT TO AT-THE-MARKET EQUITY OFFERING SALES AGREEMENT DATED MAY 25, 2018

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up